Navidea Biopharmaceuticals Inc (NAVB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Navidea Biopharmaceuticals Inc (NAVB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012246
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Navidea Biopharmaceuticals Inc (Navidea) is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. Its key product, Lymphoseek (technetium Tc 99m tilmanocept) injection, is a radiopharmaceutical agent used in intra-operative lymphatic mapping (ILM), external lymph node imaging (lymphoscintigraphy) and sentinel lymph node biopsy. The company’s products in pipeline includes lifecycle management of Lymphoseek; and NAV4694, a fluorine-18 PET (positron emission tomography) imaging agent, is being developed for the diagnosis of cognitive impairment and dementia, including Alzhemier’s disease. Navidea by utilizing its Manocept platform develops multiple precision-targeted products to identify pathways of undetected disease and provide better diagnostic accuracy, clinical decision-making and effective treatment. The company has presence in the US, Israel and the UK. Navidea is headquartered in Dublin, Ohio, the US.

Navidea Biopharmaceuticals Inc (NAVB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Navidea Biopharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Navidea Raises USD50 Million in Venture Financing 11
Partnerships 12
BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 12
Hainan Sinotau Enters into Co-Development Agreement with Navidea for Lymphoseek 13
Navidea Biopharm forms Joint Venture with Rheumco 14
Navidea Biopharma Enters into Agreement with University of California San Francisco 15
Licensing Agreements 16
Navidea Enters into License Agreement with Norgine for Lymphoseek 16
Equity Offering 17
Macrophage Therapeutics Raises USD0.5 Million in First Tranche of Private Placement 17
Asset Transactions 18
Cardinal Health Acquires Lymphoseek from Navidea Biopharma 18
Navidea Biopharmaceuticals Inc – Key Competitors 20
Navidea Biopharmaceuticals Inc – Key Employees 21
Navidea Biopharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 22
Recent Developments 23
Financial Announcements 23
Nov 08, 2017: Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results 23
Aug 08, 2017: Navidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results 25
May 09, 2017: Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results 26
Mar 29, 2017: Navidea Provides Corporate Update and Reports Full Year 2016 Results 28
Nov 03, 2016: Navidea Reports 2016 Third Quarter Financial Results 31
Aug 04, 2016: Navidea Reports Second Quarter 2016 Financial Results 33
May 17, 2016: Navidea Reports First Quarter 2016 Financial Results 36
Mar 23, 2016: Navidea Announces Fourth Quarter and Full Year 2015 Results 38
Corporate Communications 40
Sep 26, 2016: Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer 40
Apr 26, 2016: Navidea Appoints Jed Latkin as Interim Chief Operating Officer 41
Jan 11, 2016: Navidea Appoints Anton Gueth Chairman of the Board 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Navidea Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Navidea Biopharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Navidea Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Navidea Raises USD50 Million in Venture Financing 11
BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 12
Hainan Sinotau Enters into Co-Development Agreement with Navidea for Lymphoseek 13
Navidea Biopharm forms Joint Venture with Rheumco 14
Navidea Biopharma Enters into Agreement with University of California San Francisco 15
Navidea Enters into License Agreement with Norgine for Lymphoseek 16
Macrophage Therapeutics Raises USD0.5 Million in First Tranche of Private Placement 17
Cardinal Health Acquires Lymphoseek from Navidea Biopharma 18
Navidea Biopharmaceuticals Inc, Key Competitors 20
Navidea Biopharmaceuticals Inc, Key Employees 21
Navidea Biopharmaceuticals Inc, Subsidiaries 22
Navidea Biopharmaceuticals Inc, Joint Venture 22

★海外企業調査レポート[Navidea Biopharmaceuticals Inc (NAVB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sumitomo Dainippon Pharma Co., Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Huge China Holdings Limited (428):企業の財務・戦略的SWOT分析
    Huge China Holdings Limited (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Henry Schein Inc (HSIC)-医療機器分野:企業M&A・提携分析
    Summary Henry Schein, Inc. (Henry Schein) is a distributor of healthcare products and services. Its product and service portfolio consists of dental products, medical products, animal health products, software and technology and other value-added services. It offers generic and branded pharmaceutica …
  • Environmental Tectonics Corporation:企業の戦略・SWOT・財務情報
    Environmental Tectonics Corporation - Strategy, SWOT and Corporate Finance Report Summary Environmental Tectonics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • ScinoPharm Taiwan Ltd (1789):製薬・医療:M&Aディール及び事業提携情報
    Summary ScinoPharm Taiwan Ltd (ScinoPharm) provides process research and development (R&D) and active pharmaceutical ingredient (API) manufacturing services to the pharmaceutical industry. It services include custom synthesis for early phase pharmaceutical activities, brand companies and APIs for th …
  • LCI Industries:企業の戦略・SWOT・財務分析
    LCI Industries - Strategy, SWOT and Corporate Finance Report Summary LCI Industries - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Steris Corp:医療機器:M&Aディール及び事業提携情報
    Summary Steris Corp (Steris), formerly Innovative Medical Technologies, a subsidiary of Steris Plc, is a medical device company which offers infection prevention and other procedural products and services. The company offers surgical equipment and image management devices, sterile processing equipme …
  • Compal Electronics, Inc.:企業の戦略・SWOT・財務分析
    Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Immunomedics Inc (IMMU):企業の財務・戦略的SWOT分析
    Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Domino’s Pizza, Inc.:企業の戦略・SWOT・財務情報
    Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report Summary Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Skyworks Solutions Inc (SWKS):企業の財務・戦略的SWOT分析
    Skyworks Solutions Inc (SWKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Faxitron Bioptics LLC:医療機器:M&Aディール及び事業提携情報
    Summary Faxitron Bioptics LLC (Faxitron) is a medical device company that develops cabinet x-ray systems for specimen radiography, research and NDT applications. The company offers clinical products and lifescience products. Its clinical products include pathvision, corevision, biovision, localizer, …
  • Innate Pharma SA (IPH):企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a biotechnology company developing antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory hairy cell leukemia (HCL). The company is investigating drugs against …
  • Posco International Corp (047050):企業の財務・戦略的SWOT分析
    Posco International Corp (047050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Nitori Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Nitori Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nitori Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • East Central Energy:発電所・企業SWOT分析
    East Central Energy - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Engepack Embalagens SA:企業の戦略・SWOT・財務情報
    Engepack Embalagens SA - Strategy, SWOT and Corporate Finance Report Summary Engepack Embalagens SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Blueprint Medicines Corp (BPMC):医療機器:M&Aディール及び事業提携情報
    Summary Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is a drug discovery company that develops drugs for the treatment of cancers and rare diseases. The company discovers and develops selective kinase inhibitors for genomically defined cancer subsets. Its pipel …
  • Novacyt SA (ALNOV):企業の製品パイプライン分析2018
    Summary Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt deve …
  • Drugs for Neglected Diseases initiative:企業のM&A・事業提携・投資動向
    Drugs for Neglected Diseases initiative - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Drugs for Neglected Diseases initiative Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆